The National Cancer Institute turned up at the big ASCO meeting in Chicago to talk up a new study which will look to advance the development of more personalized cancer therapies. Ten pharma companies will contribute 20 drugs for a major new study that will look to determine which patients are most likely to respond, based on their genetic profile. "This is the largest and most rigorous precision oncology trial that has ever been attempted," said James Doroshow, deputy director of the NCI. Story